Monkeypox (Mpox) virus is a virulent zoonotic agent and a member of Poxviridae family. Owing to environmental, social and behavioral factors, and lack of approved vaccines or antiviral agents, the eradication of Mpox has not been successful until today.
Material and methods:
This study overviewed published data to assess predisposing factors, control strategies and antiviral therapy of mpox virus.
Results:
The recent Mpox outbreak occurred due to human behavioral factors with a cumulative total of 91,123 laboratory-confirmed cases, including 157 deaths during March 2022–September 2023. Viral immunoregulatory proteins, such as vaccinia complement control protein, inflammation modulatory protein, smallpox inhibitor of complement enzymes, chemokine binding protein, and vaccinia virus growth factor, suppress efficient responses. Host genetic variations in IL1RN (interleukin 1 Receptor Antagonist, rs452204) and IL12RB2 (rs3790567) genes and interferon-α deficiency predispose the host to more severe Mpox infection.
Conclusion:
Combination therapy and drug repositioning include promising approaches for the efficient antiviral therapy. The worldwide collaboration is required to enhance outbreak preparedness and infection control.
AdlerH, GouldS, HineP, et al.; NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: A retrospective observational study in the UK. Lancet Infect Dis, 2022; 22(8):1153–1162.
2.
AkazawaD, OhashiH, HishikiT, et al.Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. bioRxiv, 2022 2022.08.02.502485.
3.
Al RumaihZ, KelsMJT, NGE, et al.Poxvirus-encoded TNF receptor homolog dampens inflammation and protects from uncontrolled lung pathology during respiratory infection. Proc Natl Acad Sci USA, 2020; 117(43):26885–26894.
4.
AlakunleE, MoensU, NchindaG, OkekeMI. Monkeypox virus in Nigeria: Infection biology, epidemiology, and evolution. Viruses, 2020; 12(11):1257.
5.
AljabaliAA, ObeidMA, NusairMB, et al.Monkeypox virus: An emerging epidemic. Microb Pathog, 2022; 173(Pt A):105794.
6.
AltmannSE, SmithAL, DyallJ, et al.Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res, 2012; 93(2):305–308.
7.
AnwarF, HaiderF, KhanS, et al.Clinical manifestation, transmission, pathogenesis, and diagnosis of monkeypox virus: A comprehensive review. Life, 2023; 13(2):522.
8.
ArndtWD, CotsmireS, TrainorK, et al.Evasion of the innate immune type I interferon system by monkeypox virus. J Virol, 2015; 89(20):10489–10499.
9.
AssessmentRR. 2022. Monkeypox multi-country outbreak. European Centre for Dis-ease Prevention and Control.
10.
BaghbanR, GhasemianA, MahmoodiS. Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Arch Microbiol, 2023; 205(4):150.
11.
BegemanL, Van RielD, KoopmansMPG, KuikenT. The pathogenesis of zoonotic viral infections: Lessons learned by studying reservoir hosts. Front Microbiol, 2023; 14:1151524.
12.
BerhanuA, PriggeJT, SilveraPM, et al.Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob Agents Chemother, 2015; 59(7):4296–4300.
13.
BerthetN, Descorps-DeclèreS, BesombesC, et al.Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018. Sci Rep, 2021; 11(1):13085.
14.
BhatS, SahaS, GargT, et al.Insights into the challenging multi-country outbreak of Mpox: A comprehensive review. J Med Microbiol, 2023; 72(6):10.1099/jmm.0.001725.
15.
BidgoodSR, MercerJ. Cloak and dagger: Alternative immune evasion and modulation strategies of poxviruses. Viruses, 2015; 7(8):4800–4825.
16.
BourquainD, SchrickL, TischerBK, et al.Replication of cowpox virus in macrophages is dependent on the host range factor p28/N1R. Virol J, 2021; 18(1):173–176.
17.
BragazziNL, KongJD, MahroumN, et al.Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review. J Med Virol, 2023; 95(1):e27931.
18.
BrennanG, StoianAMM, YuH, et al.Molecular mechanisms of poxvirus evolution. mBio, 2023; 14(1):e0152622.
19.
BungeEM, HoetB, ChenL, et al.The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis, 2022; 16(2):e0010141.
20.
CaoS, RealegenoS, PantA, et al.Suppression of poxvirus replication by resveratrol. Front Microbiol, 2017; 8:2196.
21.
Chan-TackKM, HarringtonPR, ChoiS-Y, et al.Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. Lancet Infect Dis, 2019; 19(6):e221–e224.
22.
ChauhanRP, FogelR, LimsonJ. Overview of diagnostic methods, disease prevalence and transmission of Mpox (Formerly Monkeypox) in humans and animal reservoirs. Microorganisms, 2023; 11(5):1186.
ChiriacoM, Di MatteoG, ContiF, et al.First case of patient with two homozygous mutations in MYD88 and CARD9 genes presenting with pyogenic bacterial infections, elevated IgE, and persistent EBV viremia. Front Immunol, 2019; 10:130.
25.
ChittickG, MorrisonM, BrundageT, NicholsWG. Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox. Antiviral Res, 2017; 143:269–277.
26.
DE ClercqE. Cidofovir in the treatment of poxvirus infections. Antiviral Res, 2002; 55(1):1–13.
27.
DuboisME, HammarlundE, SlifkaMK. Optimization of peptide-based ELISA for serological diagnostics: A retrospective study of human monkeypox infection. Vector Borne Zoonotic Dis, 2012; 12(5):400–409.
28.
DuttM, KumarA, RoutM, et al.Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach. J Cell Biochem, 2023; 124(5):701–715.
29.
EldeNC, ChildSJ, EickbushMT, et al.Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell, 2012; 150(4):831–841.
30.
EstepRD, MessaoudiI, O’connorMA, et al.Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol, 2011; 85(18):9527–9542.
31.
FloresEB, BarteeMY, BarteeE. Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses. PLoS One, 2020; 15(4):e0231977.
32.
FolegattiPM, JenkinD, MorrisS, et al.; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2022; 40(35):5248–5262.
33.
ForniD, CaglianiR, MolteniC, et al.Monkeypox virus: The changing facets of a zoonotic pathogen. Infect Genet Evol, 2022; 105:105372.
34.
FrankeA, KershawO, JenckelM, et al.Fatal Cowpox Virus Infection in an Aborted Foal. Vector Borne Zoonotic Dis, 2016; 16(6):431–433.
35.
GessainA, NakouneE, YazdanpanahY. Monkeypox. N Engl J Med, 2022; 387(19):1783–1793.
36.
GiganteCM, KorberB, SeaboltMH, et al.Multiple lineages of Monkeypox virus detected in the United States, 2021–2022. bioRxiv, 2022.
37.
GongQ, WangC, ChuaiX, ChiuS. Monkeypox virus: A re-emergent threat to humans. Virol Sin, 2022; 37(4):477–482.
38.
GoodnowCC. COVID‐19, varying genetic resistance to viral disease and immune tolerance checkpoints. Immunol Cell Biol, 2021; 99(2):177–191.
39.
GrantR, NguyenLL, BrebanR. Modelling human-to-human transmission of monkeypox. Bull World Health Organ, 2020; 98(9):638–640.
40.
GrosenbachDW, HoneychurchK, RoseEA, et al.Oral tecovirimat for the treatment of smallpox. N Engl J Med, 2018; 379(1):44–53.
41.
GrosenbachDW, RussoAT, BlumED, HrubyDE. Emerging pharmacological strategies for treating and preventing mpox. Expert Rev Clin Pharmacol, 2023; 16(9):843–854.
42.
GuanH, GulI, XiaoC, et al.Emergence, phylogeography, and adaptive evolution of mpox virus. New Microbes New Infect, 2023; 52:101102.
43.
HarteMT, HagaIR, MaloneyG, et al.The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med, 2003; 197(3):343–351.
44.
HernaezB, AlcamiA. New insights into the immunomodulatory properties of poxvirus cytokine decoy receptors at the cell surface. F1000Res, 2018; 7(F1000 Faculty Rev):719.
45.
HoySM. Tecovirimat: First global approval. Drugs, 2018; 78(13):1377–1382.
46.
HuduSA, AlshrariAS, Al QtaitatA, ImranM. VP37 Protein Inhibitors for Mpox Treatment: Highlights on Recent Advances, Patent Literature, and Future Directions. Biomedicines, 2023; 11(4):1106.
47.
HugginsJ, GoffA, HensleyL, et al.Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother, 2009; 53(6):2620–2625.
48.
HughesAL, FriedmanR. Poxvirus genome evolution by gene gain and loss. Mol Phylogenet Evol, 2005; 35(1):186–195.
49.
HyunJ, MatsunamiH, KimTG, WolfM. Assembly mechanism of the pleomorphic immature poxvirus scaffold. Nat Commun, 2022; 13(1):1704–1710.
50.
ImranM, AlshammariMK, AroraMK, et al.Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects. Biomedicines, 2023; 11(2):278.
51.
IsidroJ, BorgesV, PintoM, et al.Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med, 2022; 28(8):1569–1572.
52.
IslamMA, DhamaK, IslamAA, et al.Mpox virology, epidemiology, immune response, pathology, diagnosis, potential treatments, and preventive measures: A zoonotic human disease. Front Public Health, 2025; 11:1182196.
53.
JacksonEE, JanitzAE, CarabinH. A Method to Create Directed Acyclic Graphs from Cycles of Transmission of Zoonotic and Vector-Borne Infectious Agents. Vector Borne Zoonotic Dis, 2023; 23(3):129–135.
JulanderJG, TestoriM, CheminayC, VolkmannA. Immunogenicity and protection after vaccination with a modified Vaccinia virus Ankara-vectored yellow fever vaccine in the hamster model. Front Immunol, 2018; 9:1756.
56.
KaragozA, TombulogluH, AlsaeedM, et al.Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. J Infect Public Health, 2023; 16(4):531–541.
57.
KelsMJT, NgE, Al RumaihZ, et al.TNF deficiency dysregulates inflammatory cytokine production, leading to lung pathology and death during respiratory poxvirus infection. Proc Natl Acad Sci USA, 2020; 117(27):15935–15946.
58.
KindrachukJ, ArsenaultR, KusalikA, et al.Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus. Molecular & Cellular Proteomics, 2012; 11(6):M111.015701.
59.
KinnunenPM, HenttonenH, HoffmannB, et al.Orthopox virus infections in Eurasian wild rodents. Vector Borne Zoonotic Dis, 2011; 11(8):1133–1140.
60.
KipkorirV, DhaliA, SrichawlaB, et al.The re‐emerging monkeypox disease. Tropical Med Int Health, 2022; 27(11):961–969.
61.
KumarN, AcharyaA, GendelmanHE, ByrareddySN. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun, 2022; 131:102855.
62.
LantS, Maluquer DE MotesC. Poxvirus Interactions with the Host Ubiquitin System. Pathogens, 2021; 10(8):1034.
LawsonB, RobinsonRA, TomsMP, et al.Health hazards to wild birds and risk factors associated with anthropogenic food provisioning. Phil Trans R Soc B, 2018; 373(1745):20170091.
65.
LiC, DuS, TianM, et al.The host restriction factor interferon-inducible transmembrane protein 3 inhibits vaccinia virus infection. Front Immunol, 2018; 9:228.
66.
LiuS-W, KatsafanasGC, LiuR, et al.Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses. Cell Host Microbe, 2015; 17(3):320–331.
67.
LiuZ, NailwalH, RectorJ, et al.A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation. Immunity, 2021; 54(2):247–258.e7.
68.
LuY, ZhangL. DNA-sensing antiviral innate immunity in poxvirus infection. Front Immunol, 2020; 11:1637.
69.
MahmoodiS, AmirzakariaJZ, GhasemianA. In silico design and validation of a novel multi-epitope vaccine candidate against structural proteins of Chikungunya virus using comprehensive immunoinformatics analyses. PLoS One, 2023; 18(5):e0285177.
70.
MajieA, SahaR, SarkarB. The outbreak of the monkeypox virus in the shadow of the pandemic. Environ Sci Pollut Res Int, 2023; 30(17):48686–48702.
71.
MalikS, AhmadT, AhsanO, et al.Recent developments in Mpox prevention and treatment options. Vaccines (Basel), 2023a;11(3):500.
72.
MalikS, AhmedA, AhsanO, et al.Monkeypox virus: A comprehensive overview of viral pathology, immune response, and antiviral strategies. Vaccines (Basel), 2023b;11(8):1345.
73.
Martínez-FernándezDE, Fernández-QuezadaD, Casillas-MuñozFAG, et al.Human Monkeypox: A comprehensive overview of epidemiology, pathogenesis, diagnosis, treatment, and prevention strategies. Pathogens, 2023; 12(7):947.
74.
MartinezJ, HuangX, YangY. Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog, 2010; 6(3):e1000811.
75.
MazurkovOY, KabanovAS, ShishkinaLN, et al.New effective chemically synthesized anti-smallpox compound NIOCH-14. J Gen Virol, 2016; 97(5):1229–1239.
76.
MccollumAM, ShelusV, HillA, et al.Epidemiology of human Mpox - Worldwide, 2018-2021. MMWR Morb Mortal Wkly Rep, 2023; 72(3):68–72.
MitjàO, OgoinaD, TitanjiBK, et al.Monkeypox. Lancet, 2023; 401(10370):60–74.
79.
MogensenTH. Genetic susceptibility to viral disease in humans. Clinical Microbiology and Infection, 2022; 28(11):1411–1416.
80.
MohapatraRK, MahalA, AnsariA, et al.Comparison of the binding energies of approved mpox drugs and phytochemicals through molecular docking, molecular dynamics simulation, and ADMET studies: An in silico approach. J Biosaf Biosecur, 2023; 5(3):118–132.
81.
MuckerEM, GoffAJ, ShamblinJD, et al.Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother, 2013; 57(12):6246–6253.
82.
NaveL, MargalitI, TauN, et al.Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A systematic review and meta-analysis of randomized controlled trials. Vaccines (Basel), 2023; 11(9):1410.
83.
NordgrenJ, SvenssonL. Genetic susceptibility to human norovirus infection: An update. Viruses, 2019; 11(3):226.
84.
Noy-PoratT, TamirH, AlcalayR, et al.Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization. Microbiol Spectr, 2023; 11(5):e0159823.
85.
NyameJ, PunniyakottiS, KheraK, et al.Challenges in the treatment and prevention of monkeypox infection; A comprehensive review. Acta Trop, 2023; 245:106960.
86.
OkoliGN, Van CaeseeleP, AskinN, Abou-SettaAM. Comparative evaluation of the clinical presentation and epidemiology of the 2022 and previous Mpox outbreaks: A rapid review and meta-analysis. Infect Dis (Lond), 2023; 55(7):490–508.
87.
OladoyeMJ. Monkeypox: A neglected viral zoonotic disease. Electronic Journal of Medical and Educational Technologies, 2021; 14:em2108.
88.
OliveiraGP, RodriguesRAL, LimaMT, et al.Poxvirus host range genes and virus–host spectrum: A critical review. Viruses, 2017; 9(11):331.
89.
OvsyannikovaIG, HaralambievaIH, KennedyRB, et al.Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene, 2012; 510(1):59–65.
90.
ParkerS, CrumpR, FosterS, et al.Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus. Antiviral Res, 2014; 111:42–52.
91.
PatronoLV, PléhK, SamuniL, et al.Monkeypox virus emergence in wild chimpanzees reveals distinct clinical outcomes and viral diversity. Nat Microbiol, 2020; 5(7):955–965.
92.
PolandGA, KennedyRB, ToshPK. Prevention of monkeypox with vaccines: A rapid review. Lancet Infect Dis, 2022; 22(12):e349–e358.
93.
RabaanAA, AbasAH, TalleiTE, et al.Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies. J Med Virol, 2023; 95(1):e28306.
94.
RadonićA, MetzgerS, DabrowskiPW, et al.Fatal monkeypox in wild-living sooty mangabey, Côte d’Ivoire, 2012. Emerg Infect Dis, 2014; 20(6):1009–1011.
95.
RanjanS, VashishthK, SakK, TuliHS. The emergence of Mpox: Epidemiology and current therapeutic options. Curr Pharmacol Rep, 2023; 9(3):144–153.
96.
RaoAK, SchrodtCA, MinhajFS, et al.Interim clinical treatment considerations for severe manifestations of Mpox - United States, February 2023. MMWR Morb Mortal Wkly Rep, 2023; 72(9):232–243.
97.
RcheulishviliN, MaoJ, PapukashviliD, et al.Design, evaluation, and immune simulation of potentially universal multi-epitope mpox vaccine candidate: Focus on DNA vaccine. Front Microbiol, 2023; 14:1203355.
98.
ReynoldsMG, DotyJB, MccollumAM, et al.Monkeypox re-emergence in Africa: A call to expand the concept and practice of One Health. Expert Rev Anti Infect Ther, 2019; 17(2):129–139.
99.
RizkJG, LippiG, HenryBM, et al.Prevention and Treatment of Monkeypox. Drugs, 2022; 82(9):957–963.
100.
RobinsonG, TownsendS, JahnkeMN. Molluscum contagiosum: Review and update on clinical presentation, diagnosis, risk, prevention, and treatment. Current Dermatology Reports, 2020; 9(1):83–92.
101.
RussoAT, BerhanuA, BiggerCB, et al.Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine, 2020; 38(3):644–654.
102.
RussoAT, GrosenbachDW, BraselTL, et al.Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. J Infect Dis, 2018; 218(9):1490–1499.
103.
RussoAT, GrosenbachDW, ChinsangaramJ, et al.An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther, 2021; 19(3):331–344.
104.
SaghazadehA, RezaeiN. Insights on Mpox virus infection immunopathogenesis. Rev Med Virol, 2023; 33(2):e2426.
105.
SedgerLM, OsvathSR, XuXM, et al.Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J Virol, 2006; 80(18):9300–9309.
106.
SenkevichTG, YutinN, WolfYI, et al.Ancient gene capture and recent gene loss shape the evolution of orthopoxvirus-host interaction genes. mBio, 2021; 12(4):e0149521.
107.
ShchelkunovSN. Orthopoxvirus genes that mediate disease virulence and host tropism. Advances in Virology, 2012; 2012:524743.
108.
ShchelkunovSN, YakubitskiySN, TitovaKA, et al.Enhancing the protective immune response to administration of a LIVP-GFP live attenuated vaccinia virus to mice. Pathogens, 2021; 10(3):377.
109.
ShishkinaLN, MazurkovOY, BormotovNI, et al.Safety and pharmacokinetics of the substance of the anti-smallpox drug NIOCH-14 after oral administration to laboratory animals. Viruses, 2023; 15(1):205.
110.
SicilianoNA, HerspergerAR, LacuananAM, et al.Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responses. J Virol, 2014; 88(17):10078–10091.
111.
SilvaNIO, DE OliveiraJS, KroonEG, et al.Here, there, and everywhere: The wide host range and geographic distribution of zoonotic orthopoxviruses. Viruses, 2020; 13(1):43.
112.
SklenovskaN, Van RanstM. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health, 2018; 6:241.
113.
SmeeDF, SidwellRW, KefauverD, et al.Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother, 2002; 46(5):1329–1335.
114.
SmithSK, OlsonVA, KaremKL, et al.In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother, 2009; 53(3):1007–1012.
115.
SmithSK, SelfJ, WeissS, et al.Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol, 2011; 85(17):9176–9187.
116.
StabenowJ, BullerRM, SchriewerJ, et al.A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol, 2010; 84(8):3909–3920.
117.
StittelaarKJ, NeytsJ, NaesensL, et al.Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature, 2006; 439(7077):745–748.
118.
StyczynskiA, BurgadoJ, WalterosD, et al.Seroprevalence and risk factors possibly associated with emerging zoonotic vaccinia virus in a farming community, Colombia. Emerg Infect Dis, 2019; 25(12):2169–2176.
ThetAK, KellyPJ, KasuleSN, et al.The use of Vaccinia Immune Globulin in the Treatment of Severe Mpox. Virus Infection in Human Immunodeficiency Virus/AIDS. Clin Infect Dis, 2023; 76(9):1671–1673.
121.
ThomsenMM, TyrbergT, SkaalumK, et al.Genetic variants and immune responses in a cohort of patients with varicella zoster virus encephalitis. J Infect Dis, 2021; 224(12):2122–2132.
122.
ThornhillJP, BarkatiS, WalmsleyS, et al.; SHARE-net Clinical Group. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med, 2022; 387(8):679–691.
123.
TieeMS, HarriganRJ, ThomassenHA, SmithTB. Ghosts of infections past: Using archival samples to understand a century of monkeypox virus prevalence among host communities across space and time. R Soc Open Sci, 2018; 5(1):171089.
124.
Triana-GonzálezS, Román-LópezC, MaussS, et al.Risk factors for mortality and clinical presentation of monkeypox. AIDS, 2023; 37(13):1979–1985.
125.
UllahM, LiY, MunibK, ZhangZ. Epidemiology, host range, and associated risk factors of monkeypox: An emerging global public health threat. Front Microbiol, 2023; 14:1160984.
126.
VakilMK, MansooriY, AwsiAL, et al.Individual Genetic Variability Mainly of Proinflammatory Cytokines, Cytokine Receptors and Toll‐like receptors Dictates Pathophysiology of COVID‐19 Disease. J Med Virol, 2022; 94(9):4088–4096.
127.
Van CuongN, Carrique-MasJ, Vo BeH, et al.Rodents and risk in the Mekong Delta of Vietnam: Seroprevalence of selected zoonotic viruses in rodents and humans. Vector Borne Zoonotic Dis, 2015; 15(1):65–72.
128.
VolkmannA, WilliamsonA-L, WeidenthalerH, et al.; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. Vaccine, 2021; 39(22):3067–3080.
129.
WangY, YangK, ZhouH. Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review. Int J Biol Macromol, 2023; 245:125515.
130.
WeaverJR, IsaacsSN. Monkeypox virus and insights into its immunomodulatory proteins. Immunol Rev, 2008; 225:96–113.
131.
WeiH, HuangD, FortmanJ, et al.Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol, 2009; 83(2):1115–1125.
132.
WhitehouseER, BonwittJ, HughesCM, et al.Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. J Infect Dis, 2021; 223(11):1870–1878.
133.
WilliamsRA, TruchadoDA, BenitezL. A Review on the Prevalence of Poxvirus Disease in Free-Living and Captive Wild Birds. Microbiol Res (Pavia), 2021; 12(2):403–418.
134.
World Health Organization. 2022. WHO advisory committee on variola virus research: report of the twenty-third meeting, virtual meeting, 3–4 November 2021. World Health Organization: Geneva.
135.
YangN, LunaJM, DaiP, et al.Lung type II alveolar epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against poxvirus infection. Nat Commun, 2022; 13(1):1671–1617.
136.
YangX, YangX, DuS, et al.A subunit vaccine candidate composed of Mpox virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice. Vaccines (Basel), 2023; 11(9):1420.
137.
YuH, BruneauRC, BrennanG, RothenburgS. Battle royale: Innate recognition of poxviruses and viral immune evasion. Biomedicines, 2021; 9(7):765.
138.
ZandiM, ShafaatiM, HosseiniF. Mechanisms of immune evasion of monkeypox virus. Front Microbiol, 2023; 14:1106247.
139.
ZarenezhadE, AbdulabbasHT, MarziM, et al.Nickel Nanoparticles: Applications and Antimicrobial Role against Methicillin-Resistant Staphylococcus aureus Infections. Antibiotics, 2022; 11(9):1208.
140.
ZarenezhadE, KanaanMHG, AbdollahSS, et al.Metallic Nanoparticles: Their Potential Role in Breast Cancer Immunotherapy via Trained Immunity Provocation. Biomedicines, 2023a;11(5):1245.
141.
ZarenezhadE, MarziM, AbdulabbasHT, et al.Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges. J Funct Biomater, 2023b;14(9):453.
142.
ZarenezhadE, Soltani RadMN, BehrouzS, et al.Immobilized [Cu(cdsalMeen)] on silica gel: A highly efficient heterogeneous catalyst for ‘Click’ [3 + 2] Huisgen cycloaddition. J Iran Chem SOC, 2017; 14(2):509–519.
143.
ZhangR-R, WangZ-J, ZhuY-L, et al.Rational development of multicomponent mRNA vaccine candidates against mpox. Emerg Microbes Infect, 2023; 12(1):2192815.
144.
ZhaoY, LuY, RichardsonS, et al.TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6. Nature, 2023; 620(7975):873–880.
